RLMD

Relmada TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$7.25

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$4.20

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$2.75

Analysis reference price unavailable

Analysis 2026-09-03 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-03

AI commentary

Sentiment is cautious and event-driven. Primary filings support meaningful pipeline progress and cash runway, but the NDV-01 timeline has slipped and manufacturing remains the key gate [#SEC-8K-2026-05-12] [#SEC-8K-2026-08-06]. Coverage is low, social data and analyst-revision data are unavailable, and the deterministic prior is negative; treat the stock as a monitoring situation rather than a high-conviction bullish setup.

RankAlpha Sentiment Codex - 2026-09-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31eventNDV-01 IND filing and potential Phase 3 RESCUE initiationHigh impact

The company expects to file the NDV-01 IND by year-end 2026 and initiate the Phase 3 RESCUE registrational program after clearance, with clinical sites prepared for enrollment [#SEC-8K-2026-08-06].

2026-12-31eventSepranolone IND milestone in Prader-Willi syndromeHigh impact

Relmada expects a sepranolone IND filing by year-end 2026 and a Phase 2 proof-of-concept study after clearance [#SEC-8K-2026-08-06].

2026-12-31catalystNDV-01 manufacturing execution remains the near-term gateHigh impact

Relmada says GMP manufacturing and CMC work for NDV-01 are underway, with manufacturing execution required before the planned IND filing [#SEC-8K-2026-08-06]. Completion would reduce the principal near-term execution overhang; further slippage would pressure sentiment.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-03 • Updated nightlySource: Internal modelMethodology